4 Securities Fraud Suits Filed in One Day: Microsoft, ADMA, Insulet, Embecta Face Claims

For legal professionals, these filings mark a sharp escalation in securities fraud litigation targeting product claims across tech, biopharma, and medtech. The suits allege violations of Sections 10(b) and 20(a) of the Exchange Act, predicated on disclosures that caused material stock declines. Key jurisdictional venues include the Western District of Washington, Massachusetts, and New Jersey, with varying lead plaintiff cutoff dates.

On July 10, 2026, securities law firm Bleichmar Fonti & Auld LLP (BFA Law) launched a coordinated wave of class action lawsuits against four publicly traded companies: Microsoft, ADMA Biologics, Insulet, and Embecta. Each complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, asserting that the companies and certain senior executives made materially false or misleading statements about their products, operations, or financial prospects, thereby artificially inflating stock prices before adverse disclosures caused steep declines. The lawsuits, pending in federal courts across the country, collectively underscore a rising tide of securities litigation driven by product-related failures—whether in artificial intelligence functionality, medical device safety, biopharmaceutical revenue recognition, or consumer medical goods demand.

“

A Culper Research report published March 24, 2026—titled ‘ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs.

For Microsoft, the allegations center on its Copilot generative AI assistant, which was portrayed as a driver of Azure cloud growth. The complaint claims Microsoft touted ‘best-in-class capabilities’ and widespread user adoption while allegedly knowing of severe functionality issues that caused user adoption to decline, putting Azure revenue at risk. The truth emerged when Microsoft reported disappointing second-quarter fiscal 2026 results on January 28, 2026, and Azure growth ‘did not meet expectations,’ triggering a significant stock drop. The case, captioned City of St. Clair Shores Police and Fire Retirement System, et al. v. Microsoft Corporation, is in the Western District of Washington, lead plaintiff deadline August 11, 2026.

ADMA Biologics faces claims of a ‘de facto channel stuffing scheme’ to prop up revenue growth for its flagship immune globulin product ASCENIV amid waning demand. A Culper Research report published March 24, 2026—titled ‘ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported’—allegedly revealed that ADMA inflated its top line by shipping excess product to a related-party distributor, obscuring true demand. The stock fell sharply, and the lawsuit, Mazzarino v. ADMA Biologics, Inc., is before the District of New Jersey with an August 10 lead plaintiff cutoff.

Insulet, maker of the Omnipod insulin delivery platform, is accused of misrepresenting the safety of its Omnipod 5 Automated Insulin Delivery System. On March 12, 2026, the company disclosed a manufacturing defect that caused ‘a tear in the internal tubing that delivers insulin,’ raising patient safety concerns and causing a material stock decline. The class action, Hu v. Insulet Corporation, is in the District of Massachusetts, with a lead plaintiff deadline of August 31, 2026.